Skip to content

13F-HR filed by Athyrium Capital Management, LP

Athyrium Capital Management, LP filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 10 holding rows worth $281,299,000.

Accession
0001567619-22-010942
Filed
2022-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2022

A holdings report, 10 entries on the cover page, a total value of $281,299,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $281,299,000 with VALUE read as thousands by filing date, 13F file number 028-18509. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIORA THERAPEUTICS INC74319FAB3NOTE 7.250%12/0103,500,000$73,701,000thousands by filing dateprincipal
AMRYT PHARMA LTD - SPNR ADR03217L106COMMON EQUITY8,857,268$73,250,000thousands by filing date
BIORA THERAPEUTICS INC74319F107COM29,855,847$34,633,000thousands by filing date
CAREMAX INC14171W103COM4,487,219$33,520,000thousands by filing date
Omeros Corp682143AE2NOTE 6.250%11/121,005,000$20,078,000thousands by filing dateprincipal
RVL PHARMACEUTICALS PLCG6S41R101COM8,148,832$13,772,000thousands by filing date
OMEROS CORP682143AG7NOTE 5.250% 2/118,000,000$13,538,000thousands by filing dateprincipal
Bridgebio Pharma Inc Note 2.250 percent 2/010806XAD4Convertible20,000,000$9,682,000thousands by filing dateprincipal
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK1,792,114$5,161,000thousands by filing date
SOCIETAL CDMO INC75629F109COM2,202,420$3,964,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-22-010942this filing2022-05-16acceptance time not in the bulk data set